Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC1779 in Carotid Endarterectomy Patients
2008-005246-23Phase 2Terminated
- Sponsor
- Archemix Corp.
- Start
- Oct 2008
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of egaptivon pegol in carotid atheroma (CAS), sponsored by Archemix Corp. Primary endpoint: Primary Efficacy Variable. Started Oct 2008; status: terminated.
02
Drugs
egaptivon pegol
03
Conditions
carotid atheroma (CAS)
Beyond the preview
Go deeper on 2008-005246-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005246-23.